Even the CEO Wheeler says that his company is a long shot:
Waterhouse sees the biosimilars market as a hybrid of branded drugs and generic drugs. Because they are such complex molecules, he said, doctors will use a lot more discretion in deciding which biosimilars can be used as cheaper replacements for branded biologic drugs.
Wheeler agrees that the biosimilars market is significantly different from the generics that people are used to. For one, he said, “the cost to play is a lot higher than generic.”